quality of care

Research in Review

PET Scans During Induction Chemo Contribute to Complete Response for Esophageal Cancer

01/19/2017

JCP Editors

Positron emission tomography (PET) scans during induction chemotherapy for esophageal cancer helps assess patient response to treatment and adjust their therapy, which could lead to an improved complete response rate...

...

01/19/2017

Journal of Clinical Pathways

Research in Review

Blood Condition Increases Risk of Adverse Events After ASCT in Lymphoma

01/13/2017

JCP Editors

Patients with an age-related blood condition undergoing autologous stem-cell transplantation (ASCT) for lymphoma are at greater risk of adverse outcomes, says a new study published in the Journal of Clinical...

...

01/13/2017

Journal of Clinical Pathways

Research in Review

Novel Biomarker Helps Detect Blood Cancer Responders to Chemotherapy

01/13/2017

JCP Editors

Expression of a cellular enzyme could predict the response of patients with acute myeloid leukemia (AML) to chemotherapy, according to new research. ----- Related Content Personalized Genomic Framework Predicts...

...

01/13/2017

Journal of Clinical Pathways

Quiz

Quiz: Projected Outcomes of Using Oral Targeted Therapies for CLL

01/12/2017

JCP Editors

Use of oral targeted therapies for patients with chronic lymphocytic leukemia (CLL) is projected to have which result?   A)      Improved...

Use of...

01/12/2017

Journal of Clinical Pathways

Research in Review

Prophylactic Treatment Reduces Toxicity in HER2+ Breast Cancer

01/11/2017

JCP Editors

Loperamide plus budesonide reduces the rate of toxic effects associated with neratinib for patients with human epidermal growth factor receptor-2 positive (HER2+) breast cancer, according to the results of a trial...

...

01/11/2017

Journal of Clinical Pathways

Research in Review

Two-Drug Regimen Without Chemotherapy May Treat Type of Lymphoma

01/06/2017

JCP Editors

Patients with mantle cell lymphoma may be able to forego chemotherapy in favor of induction treatment with a two-drug regimen, according to new research presented at the American Society of Hematology (ASH) annual...

...

01/06/2017

Journal of Clinical Pathways

Research in Review

Treatment Advances for Advanced-Stage NSCLC Have Increased Survival

01/05/2017

JCP Editors

Shifts in treatments of advanced-stage non-small cell lung cancer (NSCLC) have resulted in survival and spending gains over time, according to a report published in the Journal of Clinical Oncology. ----- Related...

Shifts...

01/05/2017

Journal of Clinical Pathways

Research in Review

Two-Drug Regimen Plus Bortezomib Improves Survival for Patients With Multiple Myeloma

12/29/2016

JCP Editors

The addition of bortezomib to lenalidomide with dexamethasone treatment significantly improves progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma, according to new clinical...

The...

12/29/2016

Journal of Clinical Pathways

Research in Review

Chemotherapy Regimens Comparable in Efficacy for Treatment of NSCLC

12/20/2016

JCP Editors

Two of the most common chemotherapy regimens may be comparable in terms of efficacy when used in combination with radiotherapy for treatment of non-small cell lung cancer (NSCLC), according to a recent study...

Two of...

12/20/2016

Journal of Clinical Pathways

Research in Review

A Road Map for Using Biomarkers in Clinical Practice

12/16/2016

JCP Editors

New consensus guidelines provide a "road map" for the appropriate implementation of imaging biomarkers in clinical practice. ----- Related Content Biomarkers Predict Cetuximab Performance in Metastatic Colorectal...

New...

12/16/2016

Journal of Clinical Pathways